Insights Into Acute Myeloid Leukemia (AML) 2022
Perspectives of community physicians on the treatment of AML
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Harry Erba, MD, PhD
Duke Cancer Center, Durham, NC, USA
Faculty Chair
Eytan Stein, MD
Memorial Sloan Kettering Cancer Center< New York, NY, USA
Faculty Chair
Harry Erba, MD, PhD
Duke Cancer Center, Durham, NC, USA
Faculty Chair
Thomas Leblanc, MD
Duke Cancer Center, Durham, NC, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Elie Traer, MD
Oregon Health & Science University, Portland, OR, USA
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Philadelphia, PA
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Portland, OR
- TN Oncology
More Information
- Chicago, IL
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Virtual series
- National
More Information
- Virtual series
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of AML
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region